Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Lineage Cell Therapeutics Inc
(NY:
LCTX
)
0.8753
+0.0003 (+0.03%)
Streaming Delayed Price
Updated: 12:23 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lineage Cell Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
July 13, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
June 28, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
August 05, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell's Dry AMD Gene Therapy Demonstrate Functional, Anatomical Improvements
July 20, 2021
Lineage Cell Therapeutics Inc (NYSE: LCTX) reported updated interim results from its Phase 1/2a study of its lead product candidate, OpRegen cell therapy for dry...
Via
Benzinga
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
July 20, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
June 22, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Inks Option Agreement With Amasa Therapeutics For HyStem
June 17, 2021
Lineage Cell Therapeutics Inc (NYSE: LCTX) has granted an exclusive option to Amasa Therapeutics Inc to acquire an exclusive, royalty-bearing license to use its...
Via
Benzinga
Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
June 17, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer
June 16, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
June 15, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Set to Join Russell 3000® Index and Russell Microcap® Index
June 09, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Host Webinar With Therapeutic Area Experts to Discuss Retinal Tissue Restoration Observed in Dry AMD Patients Treated With OpRegen®
June 03, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
68 Biggest Movers From Yesterday
June 02, 2021
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares surged 115.2% to close at $7.64 on Tuesday after the company announced its subsidiary, Gibson Technical Services, reached...
Via
Benzinga
Why Lineage Cell Therapeutics Stock Is Soaring Today
June 01, 2021
The company reported great news from a clinical study of its experimental cell therapy for treating eye disease.
Via
The Motley Fool
36 Stocks Moving In Tuesday's Mid-Day Session
June 01, 2021
Gainers Orbital Energy Group, Inc. (NASDAQ: OEG) shares jumped 67.3% to $5.94 after the company announced its subsidiary, Gibson Technical Services, reached an agreement with TEC...
Via
Benzinga
Lineage Cell Stock Jumps as OpRegen Shows Additional Cases Of Retinal Tissue Restoration In Mid-Stage Study
June 01, 2021
Lineage Cell Therapeutics Inc (NYSE: LCTX) has announced that restoration of retinal tissue was observed in two additional patients enrolled in the Phase 1/2a...
Via
Benzinga
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2021 Earnings Call Transcript
May 14, 2021
LCTX earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Lineage Reports First Quarter 2021 Financial Results and Highlights Significant Progress With All Three Clinical Programs
May 13, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry AMD Patients Treated With OpRegen® RPE Cells
June 01, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
May 05, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
May 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
Lineage Cell Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021
May 04, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell's Dry Age-Related Macular Degeneration Cell Therapy Associated With Stable Or Improved Vision
May 03, 2021
Lineage Cell Therapeutics Inc (NYSE: LCTX) has updated interim results from its ongoing Phase 1/2a study of its lead product candidate, OpRegen, for dry age-...
Via
Benzinga
OpRegen® Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With Geographic Atrophy
May 03, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021
April 26, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors
April 22, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Why Lineage Cell Therapeutics Stock Popped Today
April 20, 2021
The company announced a license agreement.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.